PMID- 18671772
OWN - NLM
STAT- MEDLINE
DCOM- 20081117
LR  - 20220409
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 63
IP  - 10
DP  - 2008 Oct
TI  - AllergoOncology: the role of IgE-mediated allergy in cancer.
PG  - 1255-66
LID - 10.1111/j.1398-9995.2008.01768.x [doi]
AB  - Epidemiological studies have suggested inverse associations between allergic 
      diseases and malignancies. As a proof of concept for the capability of 
      immunoglobulin E (IgE) to destruct tumor cells, several experimental strategies 
      have evolved to specifically target this antibody class towards relevant tumor 
      antigens. It could be demonstrated that IgE antibodies specific to overexpressed 
      tumor antigens have been superior to any other immunoglobulin class with respect 
      to antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) 
      reactions. In an alternative approach, IgE nonspecifically attached to tumor 
      cells proved to be a powerful adjuvant establishing tumor-specific immune memory. 
      Active Th2 immunity could also be achieved by applying an oral immunization 
      regimen using mimotopes, i.e. epitope mimics of tumor antigens. The induced IgE 
      antibodies could be cross-linked by live tumor cells leading to tumoricidic 
      mediator release. Thus, IgE antibodies may not only act in natural tumor 
      surveillance, but could possibly also be exploited for tumor control in active 
      and passive immunotherapy settings. Thereby, eosinophils, mast cells and 
      macrophages can be armed with the cytophilic IgE and become potent anti-tumor 
      effectors, able to trace viable tumor cells in the tissues. It is strongly 
      suggested that the evolving new field AllergoOncology will give new insights into 
      the role of IgE-mediated allergy in malignancies, possibly opening new avenues 
      for tumor therapy.
FAU - Jensen-Jarolim, E
AU  - Jensen-Jarolim E
AD  - Department of Pathophysiology, Center of Physiology, Pathophysiology and 
      Immunology, Medical University Vienna, Austria.
FAU - Achatz, G
AU  - Achatz G
FAU - Turner, M C
AU  - Turner MC
FAU - Karagiannis, S
AU  - Karagiannis S
FAU - Legrand, F
AU  - Legrand F
FAU - Capron, M
AU  - Capron M
FAU - Penichet, M L
AU  - Penichet ML
FAU - Rodriguez, J A
AU  - Rodriguez JA
FAU - Siccardi, A G
AU  - Siccardi AG
FAU - Vangelista, L
AU  - Vangelista L
FAU - Riemer, A B
AU  - Riemer AB
FAU - Gould, H
AU  - Gould H
LA  - eng
GR  - G0501494/MRC_/Medical Research Council/United Kingdom
GR  - P 18238/FWF_/Austrian Science Fund FWF/Austria
GR  - HHMI/Howard Hughes Medical Institute/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20080726
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Animals
MH  - Basophils/immunology
MH  - Eosinophils/immunology
MH  - Humans
MH  - Hypersensitivity/*immunology
MH  - Immunoglobulin E/*physiology/therapeutic use
MH  - Mast Cells/immunology
MH  - Neoplasms/epidemiology/*immunology/therapy
PMC - PMC2999743
MID - UKMS32996
OID - NLM: UKMS32996
EDAT- 2008/08/02 09:00
MHDA- 2008/11/18 09:00
PMCR- 2010/12/09
CRDT- 2008/08/02 09:00
PHST- 2008/08/02 09:00 [pubmed]
PHST- 2008/11/18 09:00 [medline]
PHST- 2008/08/02 09:00 [entrez]
PHST- 2010/12/09 00:00 [pmc-release]
AID - ALL1768 [pii]
AID - 10.1111/j.1398-9995.2008.01768.x [doi]
PST - ppublish
SO  - Allergy. 2008 Oct;63(10):1255-66. doi: 10.1111/j.1398-9995.2008.01768.x. Epub 
      2008 Jul 26.